When Care Becomes Leverage: Who Owns Women’s Health Infrastructure?
Women’s health needs more capital. But as clinics consolidate, the more urgent question is whether ownership models protect continuity of care, clinical autonomy, and the women who depend on both.
Special note: My book The Billion Dollar Blindspot is now available to purchase. Grab your copy and get your bonus chapter here
You are twenty-eight weeks pregnant when the email arrives. It comes at an unremarkable moment: between meetings, in a supermarket queue, or while you are waiting for the kettle to boil. The subject line is easy to miss.
Important update about your health plan.
Inside, there is a sentence that changes the shape of your pregnancy. Your OB/GYN is longer be covered by your insurance. Not because you moved, or because your doctor retired, or because anything about your pregnancy changed. But because two large organisations are negotiating a contract.
Suddenly, the doctor who knows the miscarriage you do not like to speak about, the scan that frightened you, the question you asked only after your partner had left the room, may no longer be available to you, unless you can afford to pay far more to stay.
For the insurer, it is a network negotiation. For the provider group, it is a reimbursement dispute. But for the woman reading the email, it is the prospect of beginning again with someone new, halfway through the most consequential medical event of her life.
That is not a consumer inconvenience. It is a rupture in care.
A recent dispute involving Capital Women’s Care, a large US OB/GYN network affiliated with Unified Women’s Healthcare, made that rupture visible. During negotiations with UnitedHealthcare, patients were informed that their clinicians could fall out of network. For women already under their care, the practical choice appeared brutal: find another doctor mid-pregnancy or face potentially significant out-of-pocket costs to remain with the clinical team they trusted.
The dispute was ultimately resolved but it revealed a question far larger than one contract, one insurer, or one provider group:
What happens when the infrastructure of care becomes bargaining power?
Why Scale Enters The Room
To understand why women’s health practices are consolidating, it is important to begin with the pressures facing the practices themselves. The image of the independent doctor’s office is reassuring: a local clinic, a familiar receptionist, a physician who owns her practice and answers to her patients. But independence has become increasingly difficult to sustain.
Behind the consultation room is an expanding machinery of administration: insurance claims, coding, compliance, payroll, cybersecurity, electronic records, staffing shortages, regulatory reporting, and the constant negotiation of reimbursement rates. A small practice may be clinically excellent and still lack the capital, systems, or bargaining capacity required to survive in a healthcare economy built for scale.
For an OB/GYN practice, the demands can be even broader. Care does not stop at the consultation. It may involve ultrasound, laboratory services, hospital coordination, fertility referrals, maternal-fetal medicine, mental-health support, menopause care, and increasingly, digital tools that allow women to access care outside the narrow hours of a traditional clinic. Each layer requires people, technology, working capital, and time.
This is why larger platforms have become attractive to many clinicians. They can centralise billing and administration. They can recruit staff across a wider network. They can invest in electronic systems that a single practice could not justify alone. They can build integrated pathways across fertility, pregnancy, postpartum care, gynaecology, and menopause rather than leaving women to assemble their own care from disconnected providers.
In theory, this is precisely the kind of infrastructure women’s health has lacked. Not another app asking women to track symptoms into a void, but actual clinical capacity: more appointments, more coordinated services, better tools, and practices able to remain viable in an increasingly complex system.
That is the promise of scale. And it is a promise worth taking seriously. But scale is not neutral. Its consequences depend on the incentives behind it.
The Architecture Behind The Platform
This is where the conversation about private capital in healthcare usually collapses into caricature. Either private equity is cast as the villain: a financial machine that sees a clinic only as a line item to be optimised. Or it is cast as the saviour: the only source of capital and operational expertise capable of modernising a fragmented system.
Both stories are too easy. Capital is not a single force. It arrives with a design. It has a cost. A time horizon. A return expectation. A governance structure. It may carry debt. It may require an exit by a particular date. It may reward revenue growth, margin expansion, acquisition pace, or clinical outcomes. It may give doctors meaningful authority over care decisions or reduce them to employees inside a system whose priorities are set elsewhere. Those choices are not technical details buried in transaction documents. They are the architecture of the platform.
A care group can use capital to strengthen the clinical enterprise: to hire more physicians, invest in diagnostics, reduce administrative burden, modernise systems, and give clinicians the resources to spend more time doing the work only they can do. Or it can use capital to assemble assets rapidly, load the business with obligations, and make financial engineering the central source of value creation.
From the outside, both may present the same language: innovation, efficiency, access, growth. Both may have sleek websites. Both may announce new locations. Both may describe themselves as patient-centred. But the language of a platform does not tell us what its incentives are.
Its ownership architecture does. The relevant question, then, is not whether a women’s-health platform has private capital behind it. It is what that capital requires the platform to become. That distinction matters in every corner of healthcare. It becomes especially visible when the patient cannot simply choose another provider.
The Patient Cannot Step Out of the Negotiation
Most commercial relationships contain an exit. If a bank changes its terms, you can move your account. If a mobile provider raises its prices, you can change your contract. If a supermarket stops stocking what you buy, you go elsewhere.
The inconvenience may be real. But time is usually on your side. Healthcare does not work like that. And pregnancy makes the difference impossible to ignore.
A pregnancy has its own timetable. The next appointment is not optional because a contract is unresolved. A scan cannot be deferred until a new clinic has capacity. A woman managing gestational diabetes, pre-eclampsia risk, a complicated fertility history, or the memory of a previous loss cannot simply wait for the market to settle itself.
Nor is a clinician interchangeable. Medical records can be transferred. A chart can list blood pressure readings, test results, medication, and dates. But it cannot fully carry the accumulated knowledge of a relationship: what a patient has been afraid to say, which symptoms were dismissed elsewhere, how much reassurance she needs before a procedure, or the precise moment a clinician knows that something is wrong.
This is why the language of “choice” can be misleading in maternity care. Choice assumes comparable alternatives, available at the right time, within reach, covered by insurance, and able to take responsibility for a patient immediately. Often, those conditions do not exist.
The imbalance is not that one side has acted maliciously. Provider groups need reimbursement that allows them to retain clinicians and deliver care. Insurers have a responsibility to contain costs for their members. The imbalance is more basic. The institutions can negotiate. The patient cannot suspend the need.
And when a system treats continuity as a negotiable variable, the risk does not remain with the parties at the table. It moves through the system until it reaches the person with the least power to absorb it.
The Question Capital Must Answer
For years, the women’s-health conversation has rightly focused on what is missing. The diagnostic tests that do not exist. The conditions diagnosed too late. The therapies never developed. The research questions that were never asked because female biology was treated as a complication rather than a starting point. Those gaps remain enormous. But as capital begins to move into the category, another question becomes unavoidable:
What kind of infrastructure is that capital building?
Not simply:
how many clinics were acquired?
Or how quickly did revenue grow?
Or how many patients entered the platform?
But:
who owns the relationship between a woman and her care?
What protects clinical judgement when commercial priorities tighten?
What happens to continuity when a contract fails, a strategy changes, or a platform is sold?
And which outcomes are important enough to sit beside margin, growth, and return on invested capital?
These are not peripheral questions for a mature women’s-health market. They are the questions that determine whether a category becomes more capable or merely more financialised.
The answer begins upstream. A capital allocator chooses a manager. A manager chooses a strategy. A strategy chooses an ownership model. And an ownership model decides, often quietly, which trade-offs become acceptable when growth, reimbursement, staffing, and patient care pull in different directions.
That is why capital allocation is never only about what gets funded. It is also about what gets normalised. Women’s health needs investment: in science, in clinicians, in care delivery, in technology, and in the systems that allow women to receive support across the full arc of their lives. But it needs capital with a longer view of value. Capital that understands that continuity is not a soft metric. That clinical autonomy is not a branding claim. That access is not merely a route to revenue. And that a care platform should be judged not only by what it can consolidate, but by what it can hold together.
The future of women’s health will not be decided only in laboratories, boardrooms, or funding rounds. It will also be decided in the ordinary, vulnerable moments when a woman needs to know that the care she has built her life around will still be there.
Because when care becomes leverage, the cost of getting the architecture wrong is not borne by the people negotiating the contract. It is borne by the patient waiting for the phone to ring.
ADHD Series : The Part 3 of an investigative series examining ADHD in women, late diagnosis, perimenopause, hormonal influences on cognition, diagnostic bias, women's brain health, and related healthcare innovation and investment opportunities continues next week.
That question sits at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.
I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.
It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.
Key Takeaways
Women’s health needs not only more innovation, but better care infrastructure.
The critical question is not simply how fast a platform grows, but who owns the relationship between a woman and her care.
Ownership models determine which trade-offs are accepted when growth, reimbursement, staffing, and patient care collide.
Continuity of care, clinical autonomy, affordability, and access are core outcomes—not soft metrics.
Capital allocation does not only determine what gets funded; it determines what becomes normalised.
A women’s-health platform should be judged not only by what it can consolidate, but by what it can hold together.
When care becomes leverage, the cost of misaligned incentives is borne by the patient.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
Recently saw this play out with our local health system and the largest insurance company in the state. Hundreds of thousands of people, many of them pregnant, fighting cancer, planning for surgeries etc, waiting to see if they would have to start over with a new clinic because theirs would be out of network. They did offer short term continuity for some conditions, but pregnancy wasn't one of them. Oh and in the middle of the enrollment period, so there's no option to move to a different insurer. It's obscene.
Not only have I seen this play out between a large insurer and a local ob/gyn practice group, that practice group later tried to force their choice of IUD on me. When I attempted to make my own selection, based on what they had placed earlier and fully covered by my insurance, they told me that they only stock one specific IUD and that if I wanted anything else, I would need to acquire it myself and bring it to them for placement. They suggested that I just order my desired IUD from my insurance company and "they had lots of patients who have done so" if they wanted a different IUD than the single brand/type stocked by the office.
Unsurprisingly, my insurance company was stunned and while they actually did an excellent job of trying to help me, it still required weeks of calls and messages with the insurer, the practice, and various pharmacies (and the pharmacies were likewise stunned).
It cannot be a coincidence that the practice group was sold from one private equity firm to another earlier that year.